Pharmaceuticals in Brazil Market Players Analysis¶
Products and Services¶
Based on the available data for the Brazilian pharmaceutical market in 2024 and 2023, the top players include both Brazilian and multinational companies. While specific details on the main products and services for every company are not exhaustively listed, the data provides insights into their market positioning and overall performance.
Grupo NC (includes EMS): This is a major Brazilian pharmaceutical group that held the leading position in sales to pharmacies in Brazil in 2024. [1, 5] As the controller of EMS, the group leads the Brazilian market in pharmacy sales. [1, 5]
Eurofarma: This significant pharmaceutical company operates in Brazil and showed substantial revenue growth of 22.4% in 2024, the second highest among the top 10. [1, 5] This growth propelled Eurofarma to the second position in sales to pharmacies in 2024. [1, 5]
Hypera: A prominent player in the Brazilian market, Hypera ranked third in sales to pharmacies in 2024, with a revenue evolution of 7.3%. [1, 5] Hypera is focusing on a diversification strategy, seeking to gain traction in the specialty medicines category and is also a reference in the sale of over-the-counter (MIPs) medications. [1, 5]
Novo Nordisk: This global pharmaceutical company has a strong presence and significant growth in Brazil, showing a 23.2% increase in 2024, one of the largest among the top 10. [1, 5] Novo Nordisk entered the top 3 in prescription (Rx) medicine sales in 2023, driven by its diabetes and off-label medications. [11]
Takeda: A global pharmaceutical company with operations in Brazil, Takeda was classified in the top 10 laboratories by revenue in Rx sales in Brazil in 2023. [11]
Bayer: A multinational life science company with a pharmaceuticals division active in Brazil, Bayer was also classified in the top 10 laboratories by revenue in Rx sales in Brazil in 2023. [11]
Novartis: A global healthcare company with a pharmaceutical segment, Novartis is active in the Brazilian market and was ranked among the top 10 laboratories by revenue in Rx sales in 2023. [11] Novartis is also a global top pharmaceutical company.
Aché: A Brazilian pharmaceutical company, Aché was classified among the top 10 laboratories by revenue in Rx sales in Brazil in 2023. [11]
Sanofi: A global healthcare company with a significant presence in Brazil, Sanofi was classified among the top 10 laboratories by revenue in Rx sales in Brazil in 2023. [11] Sanofi is also a global top pharmaceutical company.
AstraZeneca: A global biopharmaceutical company with operations in Brazil, AstraZeneca was ranked among the top 10 laboratories by revenue in Rx sales in Brazil in 2023 and showed significant growth in Rx revenue. [11] AstraZeneca's Rx revenue evolved by 26.6% in 2023, boosted by the medicamento Forxiga. [11] AstraZeneca is also a global top biopharmaceutical company.
While the provided data identifies these companies as top players and offers some insights into their overall revenue growth and market positioning (sales to pharmacies in 2024, Rx sales ranking in 2023), detailed lists of their main products/services and specific volume and revenue growth/decline figures per product or service are not available in the source material.
| Company | 2024 Sales to Pharmacies Ranking/Position | 2024 Revenue Growth | 2023 Rx Sales Ranking | Key Product Areas Mentioned (if any) | Estimated Volumes (2024/2023) | Estimated Revenue (2024/2023) |
|---|---|---|---|---|---|---|
| Grupo NC (includes EMS) | 1st | 9.6% growth | Not specified | Not specified | Not available | R$ 26.4 billion (2024 sales to pharmacies) |
| Eurofarma | 2nd | 22.4% growth | Not specified | Not specified | Not available | Ranked 2nd (specific revenue not provided) |
| Hypera | 3rd | 7.3% growth | Not specified | Specialty medicines, MIPs | Not available | Ranked 3rd (specific revenue not provided) |
| Novo Nordisk | Likely in top 10 | 23.2% growth | Top 3 (Rx sales) | Diabetes medications, off-label | Not available | Significant growth (specific revenue not provided) |
| Takeda | Likely in top 10 | Not specified | Top 10 (Rx sales) | Not specified | Not available | Ranked in top 10 Rx sales (specific revenue not provided) |
| Bayer | Likely in top 10 | Not specified | Top 10 (Rx sales) | Not specified | Not available | Ranked in top 10 Rx sales (specific revenue not provided) |
| Novartis | Likely in top 10 | Not specified | Top 10 (Rx sales) | Not specified | Not available | Ranked in top 10 Rx sales (specific revenue not provided) |
| Aché | Likely in top 10 | Not specified | Top 10 (Rx sales) | Not specified | Not available | Ranked in top 10 Rx sales (specific revenue not provided) |
| Sanofi | Likely in top 10 | Not specified | Top 10 (Rx sales) | Not specified | Not available | Ranked in top 10 Rx sales (specific revenue not provided) |
| AstraZeneca | Likely in top 10 | Not specified | Top 10 (Rx sales), 26.6% Rx revenue growth in 2023 | Forxiga | Not available | Ranked in top 10 Rx sales (specific revenue not provided) |
Note: A detailed comparative table showing growth/decline in volume and revenue by specific main products and services for each company could not be generated as this granular data was not available in the provided sources. The table summarizes the overall growth and ranking information available.
References¶
- Dez maiores farmacêuticas do Brasil detêm 48,6% das vendas - Abradilan
- Dez maiores farmacêuticas detêm 48,6% das vendas - Abradilan
- Dez maiores laboratórios do Brasil têm 55% do mercado - Panorama Farmacêutico